{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:28:08Z","timestamp":1774686488081,"version":"3.50.1"},"reference-count":35,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2006,7,13]],"date-time":"2006-07-13T00:00:00Z","timestamp":1152748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,9,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The interferon-\u03b3-inducible chemokine CXCL10 is highly expressed in infiltrating inflammatory cells, and in thyrocytes in patients with Graves' disease. The aim of this study was to measure serum levels of CXCL10 in relation to thyroid function and treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Serum levels of CXCL10 were measured in 22 patients with Graves' disease when hyperthyroid, when euthyroid under methimazole therapy, and 3 days after near-total thyroidectomy. They were compared with levels in three groups of age- and sex-matched controls: 44 subjects with no thyroid disorder, 44 patients with euthyroid autoimmune thyroiditis and 20 with toxic nodular goitre.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Basal serum levels of CXCL10 in patients with Graves' disease were higher than levels in patients with toxic nodular goitre or no thyroid disorder, and similar to levels in patients with autoimmune thyroiditis (mean(s.d.) 167(121), 100(24), 78(46) and 142(107) pg\/ml respectively; P &amp;lt; 0\u00b7010). Among patients with Graves' disease, serum levels of CXCL10 were significantly higher in those aged over 50 years (P = 0\u00b7010), with a hypoechoic pattern at thyroid ultrasonography (P &amp;lt; 0\u00b7001) or with hypervascularity (P = 0\u00b7001). CXCL10 levels in patients with Graves' disease decreased significantly when euthyroidism was achieved by methimazole therapy (P &amp;lt; 0\u00b7010), and a further decrease was observed after thyroidectomy (P &amp;lt; 0\u00b7010).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Serum levels of CXCL10 are higher in newly diagnosed hyperthyroid patients with Graves' disease than in those with toxic nodular goitre, and decrease when euthyroidism is achieved with antithyroid therapy. This high level may be related to the active inflammatory phase of Graves' disease. A further reduction of CXCL10 levels after thyroidectomy indicates that it is produced mainly in the thyroid in patients with autoimmune thyroid disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1002\/bjs.5401","type":"journal-article","created":{"date-parts":[[2006,7,13]],"date-time":"2006-07-13T10:47:31Z","timestamp":1152787651000},"page":"1226-1231","source":"Crossref","is-referenced-by-count":50,"title":["Serum levels of the interferon-\u03b3-inducible \u03b1 chemokine CXCL10 in patients with active Graves' disease, and modulation by methimazole therapy and thyroidectomy"],"prefix":"10.1093","volume":"93","author":[{"given":"A","family":"Antonelli","sequence":"first","affiliation":[{"name":"Metabolism Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Fallahi","sequence":"additional","affiliation":[{"name":"Metabolism Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Rotondi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathophysiology, Endocrinology Unit, University of Florence, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S M","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Metabolism Unit, Department of Internal Medicine, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Serio","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathophysiology, Endocrinology Unit, University of Florence, Florence, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Miccoli","sequence":"additional","affiliation":[{"name":"Endocrine Surgery Unit, University of Pisa, Pisa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2006,7,13]]},"reference":[{"key":"2021070906445498400_bib1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1074-7613(00)80165-X","article-title":"Chemokines: a new classification system and their role in immunity","volume":"12","author":"Zlotnik","year":"2000","journal-title":"Immunity"},{"key":"2021070906445498400_bib2","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/jlb.62.5.554","article-title":"The role of CXC chemokines in the regulation of angiogenesis in non-small cell lung cancer","volume":"62","author":"Arenberg","year":"1997","journal-title":"J Leukoc Biol"},{"key":"2021070906445498400_bib3","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/35065016","article-title":"Involvement of chemokine receptors in breast cancer metastasis","volume":"410","author":"Muller","year":"2001","journal-title":"Nature"},{"key":"2021070906445498400_bib4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF03345149","article-title":"Role for interferon-gamma inducible chemokines in endocrine autoimmunity: an expanding field","volume":"26","author":"Rotondi","year":"2003","journal-title":"J Endocrinol Invest"},{"key":"2021070906445498400_bib5","doi-asserted-by":"crossref","first-page":"510","DOI":"10.2337\/diacare.24.3.510","article-title":"Elevated serum IP-10 levels observed in type 1 diabetes","volume":"24","author":"Shimada","year":"2001","journal-title":"Diabetes Care"},{"key":"2021070906445498400_bib6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s00125-002-0879-5","article-title":"Serum concentrations of the interferon-gamma-inducible chemokine IP-10\/CXCL10 are augmented in both newly diagnosed type I diabetes mellitus patients and subjects at risk of developing the disease","volume":"45","author":"Nicoletti","year":"2002","journal-title":"Diabetologia"},{"key":"2021070906445498400_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0002-9440(10)64171-5","article-title":"Expression of IP-10\/CXCL10 and Mig\/CXCL9 in the thyroid and increased serum levels of IP-10\/CXCL10 in the serum of patients with recent onset Graves' disease","volume":"161","author":"Romagnani","year":"2002","journal-title":"Am J Pathol"},{"key":"2021070906445498400_bib8","doi-asserted-by":"crossref","first-page":"5496","DOI":"10.1210\/jc.2004-0977","article-title":"High levels of circulating CXC chemokine ligand 10 are associated with chronic autoimmune thyroiditis and hypothyroidism","volume":"89","author":"Antonelli","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2021070906445498400_bib9","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1530\/eje.1.01847","article-title":"Increase of interferon-gamma inducible alpha chemokine CXCL10 but not beta chemokine CCL2 serum levels in chronic autoimmune thyroiditis","volume":"152","author":"Antonelli","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"2021070906445498400_bib10","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1210\/jcem.86.10.7953","article-title":"Thyrocytes from autoimmune thyroid disorders produce the chemokines IP-10 and Mig and attract CXCR3+ lymphocytes","volume":"86","author":"Garcia-Lopez","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2021070906445498400_bib11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1046\/j.1365-2265.2003.01824.x","article-title":"Detection and localization of chemokine gene expression in autoimmune thyroid disease","volume":"59","author":"Kemp","year":"2003","journal-title":"Clin Endocrinol"},{"key":"2021070906445498400_bib12","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1172\/JCI9775","article-title":"Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity","volume":"107","author":"Romagnani","year":"2001","journal-title":"J Clin Invest"},{"key":"2021070906445498400_bib13","first-page":"2873","article-title":"A one-tube polymerase chain reaction protocol demonstrates CC chemokine overexpression in Graves' disease glands","volume":"84","author":"Ashhab","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2021070906445498400_bib14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1046\/j.1365-2249.2001.01683.x","article-title":"Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease","volume":"126","author":"Antonelli","year":"2001","journal-title":"Clin Exp Immunol"},{"key":"2021070906445498400_bib15","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1007\/s00464-003-9225-3","article-title":"Video-assisted thyroidectomy for Graves' disease: report of a preliminary experience","volume":"18","author":"Berti","year":"2004","journal-title":"Surg Endosc"},{"key":"2021070906445498400_bib16","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1001\/jama.281.17.1588","article-title":"Thyroid cancer in patients with hepatitis C infection","volume":"281","author":"Antonelli","year":"1999","journal-title":"JAMA"},{"key":"2021070906445498400_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1089\/105072503322021142","article-title":"Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer","volume":"13","author":"Antonelli","year":"2003","journal-title":"Thyroid"},{"key":"2021070906445498400_bib18","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00006231-199804000-00008","article-title":"Ultrasonographic versus scintigraphic measurement of thyroid volume in patients referred for 131I therapy","volume":"19","author":"Wesche","year":"1998","journal-title":"Nucl Med Commun"},{"key":"2021070906445498400_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1530\/eje.0.1420022","article-title":"Grey scale thyroid ultrasonography in the evaluation of patients with Graves' disease","volume":"142","author":"Vitti","year":"2000","journal-title":"Eur J Endocr"},{"key":"2021070906445498400_bib20","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1089\/thy.1995.5.25","article-title":"Role of neck ultrasonography in the follow-up of patients operated on for thyroid cancer","volume":"5","author":"Antonelli","year":"1995","journal-title":"Thyroid"},{"key":"2021070906445498400_bib21","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/BF03349833","article-title":"Thyroid blood flow evaluation by color-flow Doppler sonography distinguishes Graves' disease from Hashimoto's thyroiditis","volume":"18","author":"Vitti","year":"1995","journal-title":"J Endocrinol Invest"},{"key":"2021070906445498400_bib22","first-page":"2976","article-title":"Increased serum concentrations of interleukin-6 (IL-6) and soluble IL-6 receptor in patients with Graves' disease","volume":"81","author":"Salvi","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2021070906445498400_bib23","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1530\/eje.0.1430197","article-title":"Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking","volume":"143","author":"Salvi","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"2021070906445498400_bib24","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1089\/thy.2000.10.815","article-title":"Increased levels of serum interleukin-18 in Graves' disease","volume":"10","author":"Miyauchi","year":"2000","journal-title":"Thyroid"},{"key":"2021070906445498400_bib25","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1530\/eje.0.1320668","article-title":"Serum levels of interleukin 6 and tumor necrosis factor-alpha in hyperthyroid patients before and after propylthiouracil treatment","volume":"132","author":"Celik","year":"1995","journal-title":"Eur J Endocrinol"},{"key":"2021070906445498400_bib26","first-page":"78","article-title":"Serum interleukin-6 and bone metabolism in patients with thyroid function disorders","volume":"82","author":"Lakatos","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2021070906445498400_bib27","first-page":"435","article-title":"Serum cytokines in thyrotoxicosis","volume":"84","author":"Siddiqi","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2021070906445498400_bib28","first-page":"355","article-title":"Analysis of cytokine gene expression in Graves' disease and multinodular goiter","volume":"79","author":"Watson","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2021070906445498400_bib29","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1055\/s-2003-41624","article-title":"Soluble tumour necrosis factor-alpha receptor I and interleukin-6 as markers of activity in thyrotoxic Graves' disease","volume":"35","author":"Pichler","year":"2003","journal-title":"Horm Metab Res"},{"key":"2021070906445498400_bib30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1365-2265.2002.01629.x","article-title":"Serum concentrations of tumour necrosis factor-alpha (TNF-alpha) and soluble TNF-alpha receptor p55 in patients with hypothyroidism and hyperthyroidism before and after normalization of thyroid function","volume":"57","author":"Diez","year":"2002","journal-title":"Clin Endocrinol"},{"key":"2021070906445498400_bib31","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1365-2362.1995.tb01981.x","article-title":"Increased serum interleukin-1 beta during treatment of hyperthyroidism with antithyroid drugs","volume":"25","author":"Tsatsoulis","year":"1995","journal-title":"Eur J Clin Invest"},{"key":"2021070906445498400_bib32","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198411223112106","article-title":"Antithyroid drugs","volume":"311","author":"Cooper","year":"1984","journal-title":"N Engl J Med"},{"key":"2021070906445498400_bib33","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1365-2265.1984.tb03456.x","article-title":"Evidence for an effect of antithyroid drugs on the natural history of Graves' disease","volume":"21","author":"Weetman","year":"1984","journal-title":"Clin Endocrinol"},{"key":"2021070906445498400_bib34","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0140-6736(92)92171-B","article-title":"Antithyroid drugs and release of inflammatory mediators by complement-attacked thyroid cells","volume":"340","author":"Weetman","year":"1992","journal-title":"Lancet"},{"key":"2021070906445498400_bib35","first-page":"58","article-title":"Proinflammatory cytokine levels in hyperthyroidism","volume":"26","author":"Senturk","year":"2003","journal-title":"Clin Invest Med"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbjs.5401","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/93\/10\/1226\/36686226\/bjs5401.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/93\/10\/1226\/36686226\/bjs5401.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T15:36:44Z","timestamp":1625845004000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/93\/10\/1226\/6149659"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,7,13]]},"references-count":35,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2006,7,13]]},"published-print":{"date-parts":[[2006,9,15]]}},"URL":"https:\/\/doi.org\/10.1002\/bjs.5401","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"value":"0007-1323","type":"print"},{"value":"1365-2168","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2006,10]]},"published":{"date-parts":[[2006,7,13]]}}}